Drugs / PRT1419
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05107856 | Mar 2022 → Jan 2024 | acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myelomonocytic leukemia, follicular lymphoma +3 | Prelude Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT04837677 | Aug 2021 → Feb 2023 | breast cancer, cervical cancer, esophageal cancer, head and neck cancer +3 | Prelude Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04543305 | Sep 2020 → Mar 2022 | acute myeloid leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma, plasma cell myeloma | Prelude Therapeutics | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRT1419 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05107856 ↗ |
| Action | Inhibit | “a myeloid cell leukemia 1 (MCL1) inhibitor” NCT04543305 ↗ |
| Route | Oral | “PRT1419 will be administered orally” NCT04543305 ↗ |
| Target | MCL1 | “a myeloid cell leukemia 1 (MCL1) inhibitor” NCT04543305 ↗ |